3NT Medical is a technology company.
3NT Medical is a technology company.
3NT Medical has raised $1.0M across 1 funding round.
3NT Medical has raised $1.0M in total across 1 funding round.
3NT Medical has raised $1.0M in total across 1 funding round.
3NT Medical's investors include MedTech Entrepreneurs Management GmbH.
3NT Medical is an Israel-based medical device company developing sterile, single-use endoscopes tailored for ear, nose, and throat (ENT) surgeons to enable minimally invasive diagnosis and treatment of otolaryngology disorders.[2][4] Its lead products include the Colibri™ Micro ENT Scope for intuitive two-handed ear surgery and the Peregrine™ Drivable ENT Scope (formerly Sinusway) for navigating narrow nasal anatomy, serving ENT specialists by addressing limitations of reusable endoscopes like cross-contamination risks and poor maneuverability.[2][3][4][6] The company has raised $15M in corporate minority funding from Hoya Corp., holds 15 patents in medical equipment and surgical procedures, and is expanding availability in select markets with offices in Rosh Ha’ayin, Israel, and Short Hills, NJ, USA.[2][3][4][5]
3NT Medical was co-founded by Ehud Bendory (CEO, with 17 years as a medical device entrepreneur, former 8200 IDF Intelligence Officer, B.Sc. Electrical Engineering & MBA) and Eran Bendory (Chief Technologist, 1980-2024), alongside Tal Shchory (VP R&D & COO, 17 years in medical devices, B.Sc. Electrical Engineering & MBA).[5] The idea emerged from expertise in endoscopic technology to solve ENT-specific challenges, such as accessing the farthest nasal reaches and stable ear surgery, leading to the development of the drivable Sinusway endoscope.[2][6] Early traction included $15M funding from Hoya Corp. about 7 years ago, 3 clinical trials, patents filed, and product launches like Colibri and Peregrine, with ongoing market expansion despite the loss of co-founder Eran Bendory.[1][2][3][4][5]
3NT Medical rides the wave of disruptive medtech innovation in endoscopy, where single-use devices address healthcare demands for infection control post-COVID and minimally invasive procedures amid rising ENT disorder prevalence.[2][3] Timing aligns with market growth in endoscopy devices, driven by aging populations, technological advances, and regulatory pushes for disposable tools to reduce hospital-acquired infections.[2][3] Favorable forces include Hoya Corp. backing and U.S./Israel medtech hubs, positioning 3NT to influence ENT standards by challenging reusable endoscope dominance and expanding sterile alternatives globally.[2][3][4]
3NT Medical is poised for growth through broader product availability, leveraging its $15M funding, clinical trials, and patent portfolio to capture share in the expanding endoscopy market.[1][2][3] Trends like AI-enhanced imaging and further single-use adoption will shape its path, potentially via partnerships or acquisitions by players like Hoya. Its influence may evolve by redefining ENT tools for precision and safety, building on founder legacies to scale from niche innovator to ecosystem staple—advancing the promise of ENT surgery taken further.[3][4][5]
3NT Medical has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Series C in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $1.0M Series C | MedTech Entrepreneurs Management GmbH |